Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention and Treatment
Urology, 04/06/2012Azzouni F et al.
The observation that males born with 5α–R 2 deficiency have never been reported to develop prostate cancer stimulated interest in development of 5 α–R inhibitors. Thus far, 2 5α–R inhibitors are approved for clinical use.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.